Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M. Scirica, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 773-786
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail Kosiborod, John Deanfield, Richard Pratley, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 949-961
Closed Access | Times Cited: 62
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 11
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis, Maria Nikolaou
Biomolecules (2025) Vol. 15, Iss. 2, pp. 213-213
Open Access | Times Cited: 4
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Efficacy of GLP-1 Receptor Agonists in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Shoaib Waqas, Muhammad Umer Sohail, Muhammad Saad, et al.
Journal of Cardiac Failure (2025)
Open Access | Times Cited: 3
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access | Times Cited: 2
Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic
Nikolaos Theodorakis, Maria Nikolaou, Andrew J. Krentz
Biomolecules (2025) Vol. 15, Iss. 3, pp. 373-373
Open Access | Times Cited: 1
Cardioprotective effects of semaglutide on isolated human ventricular myocardium
Thomas Krammer, Maria J. Baier, Philipp Hegner, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
Can a New Commission Make America Healthy Again?
Lawrence O. Gostin, Sarah Wetter, Peter Lurie
JAMA Health Forum (2025) Vol. 6, Iss. 3, pp. e251304-e251304
Open Access | Times Cited: 1
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Takeshi Kitai, Shun Kohsaka, Takao Kato, et al.
Journal of Cardiac Failure (2025)
Closed Access | Times Cited: 1
GLP-1 and its analogues: Does sex matter?
Stina Börchers, Karolina P. Skibicka
Endocrinology (2024)
Open Access | Times Cited: 4
Thérapeutiques de l’obésité et maladies cardiovasculaires
Pierre Bel Lassen, Judith Aron‐Wisnewsky
Archives des Maladies du Coeur et des Vaisseaux - Pratique (2025)
Closed Access
Obésité et insuffisance cardiaque
Richard Isnard, L. Legrand, Françoise Pousset
Archives des Maladies du Coeur et des Vaisseaux - Pratique (2025)
Closed Access
AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists
Xin Wang, Linxi Wang
(2025), pp. 4-4
Closed Access
Tratamiento actual de la obesidad: una historia sobre creencias, apegos y confrontación
José M. Balibrea, María Recarte-Rico, María Dolores Frutos
Cirugía Española (2025)
Closed Access
Antiobesity Medications in Patients With Heart Failure
Sureya F Hussani, Kelly Nguyen, Ka Man Yu, et al.
JACC Heart Failure (2025)
Closed Access
Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes
Yan‐Ru Lou, Yongping Xu, Yifeng Xiong, et al.
Clinical Pharmacokinetics (2025)
Closed Access
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Thomaz Alexandre Costa, Josephine Harrington
Current Opinion in Cardiology (2025)
Closed Access
Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2024
Majken T. Wingo, Carl A Andersen, Nadir M Bhuiyan, et al.
The American Journal of Medicine (2025)
Closed Access
Deep Learning-Enhanced Light Sheet Microscopy Unveils Semaglutide Impact on Cardiac Fibrosis
Sheyla Barrado-Ballestero, Sarah Torp Yttergren, Max Hahn, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art
Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou
Heart Failure Reviews (2025)
Closed Access
Obesity accelerates cardiovascular ageing
Celia Rupérez, Frank Madeo, Rafael de Cabo, et al.
European Heart Journal (2025)
Open Access
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Toshihide Izumida, Koichiro Kinugawa
International Journal of Heart Failure (2025) Vol. 7
Open Access
Antifibrotic Therapies for Metabolic Dysfunction-associated Steatotic Liver Disease
Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto, et al.
JHEP Reports (2025), pp. 101421-101421
Open Access
Updates from the 2025 American Diabetes Association guidelines on standards of medical care in diabetes
Dipti Tiwari, Wann Jia Loh, Tar Choon Aw
(2025)
Closed Access
Page 1 - Next Page

Scroll to top